Why Amgen, Inc.’s Kyprolis FOCUS Failure Is a Big Deal

August 14, 2014 12:58 AM

18 0

Amgen 's Kyprolis has passed multiple clinical trials, but the failure today will overshadow the rest.

That's because the only thing that really matters to cancer patients is survival. Does the drug help the patient live longer?

Read more

To category page